CorMedix (CRMD) Convertible Debt (2012 - 2019)

CorMedix (CRMD) posted Convertible Debt of $6.7 million for Q2 2019, up 4.77% sequentially from $6.4 million in Q1 2019.

CorMedix (CRMD) Convertible Debt (2012 - 2019) Analysis & Trends

CorMedix has reported Convertible Debt for 4 years, with the latest figure at $6.7 million in Q2 2019.

Quarterly Convertible Debt changed N/A year-over-year to $6.7 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $6.7 million (changed N/A YoY) and the FY2018 annual result came in at $6.1 million, changed N/A from the prior year.
Convertible Debt grew to $6.7 million in Q2 2019 per CRMD's latest filing, from $6.4 million in the prior quarter.
Over five years, Convertible Debt peaked at $6.7 million in Q2 2019 and troughed at $6.1 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn

Download Data